A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy resistance. The research, led by Arul M. Chinnaiyan, M.D., Ph.D., identifies the UBA1 enzyme, already known to contribute to tumor growth, as a key mediator for the immune response to a tumor. Inhibiting its activity increases T-cell recruitment and lowers tumor resistance to immunotherapies.
Medical Xpress – latest medical and health news stories
